Search Results - Lidan Yi

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Cover Image

    Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis by Chongqing Tan, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Lidan Yi, Qiao Liu

    Published 2023
    Connect to this object online.
    Book

    Save to List
    Saved in:
  2. 2
    Cover Image

    Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  3. 3
    Cover Image

    Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  4. 4
    Cover Image

    First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis by Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

    Published 2021
    Connect to this object online.
    Book

    Save to List
    Saved in:
  5. 5
    Cover Image

    Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50% by Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  6. 6
    Cover Image

    Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell L... by Xia Luo, Qiao Liu, Zhen Zhou, Lidan Yi, Liubao Peng, Xiaomin Wan, Xiaohui Zeng, Chongqing Tan, Sini Li

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  7. 7
    Cover Image

    Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer by Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan

    Published 2021
    Connect to this object online.
    Book

    Save to List
    Saved in:
  8. 8
    Cover Image

    Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis by Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: